The strength of more detailed data on GSK’s shingles vaccine in older people from the Phase III ZOE-70 study raises prospects Shingrix can advance into a market that Merck’s Zostavax currently has to itself.
Chances GlaxoSmithKline PLC can turn the tables on rival Merck & Co. Inc. with its vaccine against varicella zoster, the virus that causes shingles, were strengthened by confirmation GSK’s Shingrix achieved high efficacy in adults aged 70 years and over in a pivotal Phase III trial.
Results from its Phase III ZOE-70 trial assessing its shingles vaccine candidate in adults aged 70 and over were published...
Create an account to read this article
Already a subscriber?
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
